Analysts, along with Dr. Yaacov Anziska, will discuss Sarepta’s (SRPT) Elevidys’ risk/benefit profile on an Analyst/Industry conference call to be held on October 17 at 10 am.
Claim 30% Off TipRanks
Forget margin or options. Here's how the pros trade SRPTPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Cautious Hold Rating on Sarepta Therapeutics Amid Promising but Inconclusive Sirolimus Findings
- NY panel recommends Medicaid pause coverage of DMD drug, STAT reports
- KalVista appoints Bilal Arif as COO, Linea Aspesi as CPO
- Iron Mountain, Lennar, Sarepta, Paycom, Guardant: Trending by Analysts
- Pfizer to acquire Metsera, Oracle names new CEOs: Morning Buzz